| sess_SDA-2026-04-16- | How does the human brain connectome reorganize in Alzheimer's disease, and what | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-16-frontier-connectomics-84acb35a |
| sess_SDA-2026-04-16- | There's a clear disconnect between improved mechanistic understanding of AD and | 0.50 | 7 | 4 | completed | 2026-04-18 | SDA-2026-04-16-gap-pubmed-20260410-145418-c1527e7b |
| sess_SDA-2026-04-16- | What are the shared DNA methylation age acceleration and histone modification pa | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-16-gap-epigenetic-adpdals |
| sess_SDA-2026-04-16- | While RGS6 deficiency causes Parkinson's-like pathology, whether enhancing RGS6 | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-16-gap-pubmed-20260410-145520-5692b02e |
| sess_SDA-2026-04-17- | Analyze the spectrum of microglial activation states (DAM, homeostatic, inflamma | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-17-gap-20260416-220243 |
| sess_SDA-2026-04-17- | Analyze the spectrum of microglial activation states (DAM, homeostatic, inflamma | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-17-gap-microglial-subtypes-pharmaco-202604170000 |
| sess_SDA-2026-04-17- | While RGS6 deficiency causes Parkinson's-like pathology, whether enhancing RGS6 | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-17-gap-pubmed-20260410-145520-5692b02e |
| sess_SDA-2026-04-17- | The fundamental premise remains unvalidated despite extensive mechanistic specul | 0.50 | 7 | 4 | completed | 2026-04-18 | SDA-2026-04-17-gap-debate-20260417-033037-c43d12c2 |
| sess_SDA-NEUROINFLAM | What is the optimal blood-based biomarker panel combining established markers (G | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-NEUROINFLAM-BIOMARKERPANEL-0b9129bc |
| sess_SDA-2026-04-18- | The debate highlighted compelling correlative evidence for ferroptosis markers i | 0.50 | 4 | 4 | completed | 2026-04-18 | SDA-2026-04-18-gap-debate-20260417-032952-48bdcbea |
| sess_SDA-2026-04-16- | The debate framework mentioned multiple microglial subtypes but no analysis was | 1.00 | 3 | 4 | completed | 2026-04-18 | SDA-2026-04-16-gap-debate-20260410-112642-fffdca96 |
| ds-SDA-2026-04-16-ga | Ferroptosis in ALS and motor neuron disease: GPX4, lipid peroxidation, and iron | 0.59 | 7 | 5 | completed | 2026-04-17 | SDA-2026-04-16-gap-ferroptosis-als-d2fb6bf796ed |
| DEBATE-BIOMNI-125926 | Is the gut microbiome a driver of PD pathology via SCFA depletion, or is dysbios | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-MICROBIO-337ee37a |
| DEBATE-BIOMNI-25ad6c | Does the hybrid DAM + interferon-response microglial population represent a nove | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-SCRNA_AN-248caecc |
| DEBATE-BIOMNI-f7eed7 | Is REST the master regulator of neuronal vulnerability in AD, or is it one of se | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-GENE_REG-785b71fe |
| DEBATE-BIOMNI-46c249 | Does fine-mapping to median 3-variant credible sets provide sufficient resolutio | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-FINE_MAP-215bc2c6 |
| DEBATE-BIOMNI-9892a9 | Does the BIN1 non-coding variant mechanism provide a druggable target, or is tra | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-VARIANT_-b5b8e32f |
| DEBATE-BIOMNI-0aafda | Are AD polygenic risk scores ready for clinical use in risk stratification, or d | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-POLYGENI-b3028c7a |
| DEBATE-BIOMNI-b0e2d2 | Is a 3-marker prognostic index clinically actionable for MCI patients, or does t | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-SURVIVAL-3e217f4d |
| DEBATE-BIOMNI-18feeb | Is the amyloid concentration in AD clinical trials rational given lecanemab's ap | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-CLINICAL-b7a71edd |
| DEBATE-BIOMNI-f2a534 | Is a 12-protein CSF panel superior to existing plasma p-tau217 for clinical AD p | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-PROTEOMI-c4a33049 |
| DEBATE-BIOMNI-33e7c0 | Is Cas13-based 4R-tau silencing feasible given collateral cleavage risks in post | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-CAS13_PR-d6f415f0 |
| DEBATE-BIOMNI-8a559d | Can computationally designed binders against alpha-synuclein realistically trans | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-BINDER_D-0657a9ed |
| DEBATE-BIOMNI-cedbd5 | Should clinical practice adopt multi-modal biomarker panels now, or wait for sin | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-BIOMARKE-34ec007c |
| DEBATE-BIOMNI-baf74a | Is the APOE-TREM2 communication axis a therapeutic target, or is disrupting it r | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-CELL_CEL-a7eed9c5 |
| DEBATE-BIOMNI-5b49bd | Is TYROBP a genuine therapeutic target in AD, or is it a downstream marker of mi | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-GENE_COE-55fc5237 |
| DEBATE-BIOMNI-aff2a8 | Do spatial transcriptomic neighborhoods provide sufficient discriminative power | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-SPATIAL_-c2b61633 |
| sess_SDA-2026-04-16- | test | 0.65 | 0 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-20260416-133111 |
| sess_SDA-2026-04-16- | The abstract explicitly questions whether AD's hallmark pathologies induce choli | 0.95 | 7 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-pubmed-20260411-082446-2c1c9e2d |
| sess_SDA-2026-04-16- | The abstract reports that Alectinib binds C1q with high affinity, but this is me | 0.94 | 7 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-pubmed-20260410-095709-4e97c09e |
| sess_SDA-2026-04-04- | Investigate the therapeutic potential of clearing senescent cells (senolytics) t | 0.75 | 3 | 4 | completed | 2026-04-16 | SDA-2026-04-04-gap-senescent-clearance-neuro |
| sess_SDA-2026-04-16- | The skeptic raised evidence that APOE4 carriers show enhanced cholesterol synthe | 0.71 | 3 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e |
| sess_SDA-2026-04-16- | While the study establishes LRRK2 as a lysosomal swelling sensor and notes that | 0.85 | 3 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867 |
| sess_SDA-2026-04-16- | While the study demonstrates dose-response relationships between amyloid levels | 0.76 | 3 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-pubmed-20260410-192526-f2bbb9ab |
| sess_SDA-2026-04-16- | How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synucle | 0.84 | 3 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-20260416-121711 |
| sess_SDA-2026-04-16- | The debate framework identified synaptic vesicle protein modifications as critic | 0.73 | 3 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-debate-20260411-065018-92a34465 |
| sess_SDA-2026-04-16- | The abstract suggests that Aβ-tau synergy could explain negative results from an | 0.65 | 3 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974 |
| sess_SDA-2026-04-12- | The debate revealed conflicting evidence about C1q's role - some studies show it | 0.58 | 0 | 4 | completed | 2026-04-16 | SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1 |
| sess_SDA-2026-04-12- | The debate revealed that stress granules can be both neuroprotective and patholo | 0.86 | 0 | 4 | completed | 2026-04-16 | SDA-2026-04-12-gap-debate-20260410-112915-df7f8ad0 |
| sess_SDA-2026-04-12- | The debate revealed that DNAJB6 evidence is limited to polyglutamine aggregation | 0.79 | 3 | 4 | completed | 2026-04-16 | SDA-2026-04-12-gap-debate-20260410-112945-6a9ce0a3 |
| sess_SDA-2026-04-12- | The debate revealed conflicting evidence about whether HCN1 downregulation drive | 0.93 | 6 | 4 | completed | 2026-04-16 | SDA-2026-04-12-gap-debate-20260410-112951-80857f4e |
| sess_SDA-2026-04-12- | The debate highlighted major uncertainty about whether rodent glymphatic finding | 0.95 | 6 | 4 | completed | 2026-04-16 | SDA-2026-04-12-gap-debate-20260410-113010-76c2ddfd |
| sess_SDA-2026-04-16- | The debate revealed conflicting evidence about whether TRPML1 activation rescues | 0.46 | 0 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-debate-20260410-113045-27c7b314 |
| sess_SDA-2026-04-13- | The debate framework identified functional hyperconnectivity as potentially repr | 0.95 | 7 | 4 | completed | 2026-04-16 | SDA-2026-04-13-gap-debate-20260411-065001-076e4fa7 |
| sess_SDA-2026-04-13- | The P2X7 hypothesis relies on TRIM46-mediated actin polymerization in astrocytes | 0.95 | 7 | 4 | completed | 2026-04-16 | SDA-2026-04-13-gap-debate-20260412-094638-cd9ef05d |
| sess_SDA-2026-04-13- | The abstract shows that IDH mutations reduce protein enzymatic activity yet para | 0.95 | 7 | 4 | completed | 2026-04-16 | SDA-2026-04-13-gap-pubmed-20260410-105951-ce87670d |
| sess_SDA-2026-04-13- | The study demonstrates that high-neural glioblastoma cells form synapses with ne | 0.62 | 0 | 4 | completed | 2026-04-16 | SDA-2026-04-13-gap-pubmed-20260410-171918-9936a995 |
| sess_SDA-2026-04-13- | PGC-1α is known to enhance mitochondrial function and antioxidant responses, yet | 0.70 | 0 | 4 | completed | 2026-04-16 | SDA-2026-04-13-gap-pubmed-20260410-171850-e91bcc0d |
| sess_SDA-2026-04-13- | The study shows PSEN2 is essential in cortical and dopaminergic neurons and regu | 0.68 | 0 | 4 | completed | 2026-04-16 | SDA-2026-04-13-gap-pubmed-20260410-173032-9318ca0d |
| sess_SDA-2026-04-13- | The study identifies KCNJ2 as a therapeutic target through CRISPR screening but | 0.71 | 0 | 4 | completed | 2026-04-16 | SDA-2026-04-13-gap-pubmed-20260410-173045-28238f1f |